Cancer data ecosystem
Ended Awarded Last action
- Contract number
- HHSN26100038
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,528,739
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $2,528,739.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | -$696,863 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,225,602 |
About this award
This is a $2,528,739 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is part of the NCI's Cancer Data Ecosystem program and has an ultimate completion date of April 30, 2026. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a wide range of biomedical research and facilities support services. Through this contract, Leidos will contribute to the NCI's research efforts across various disease areas, including cancer, HIV/AIDS, influenza, COVID-19, and gene therapy. Leidos Biomedical Research Inc. has previously supported the NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC) program and COVID-19 research activities under the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program.
Quick answers
Who was awarded contract HHSN26100038?
HHSN26100038 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2017.
How much is contract HHSN26100038 worth?
The government has obligated $2,528,739 on HHSN26100038.
Is contract HHSN26100038 an order under another contract?
Yes. HHSN26100038 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100038 competed?
The extent of competition for HHSN26100038 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award